Nektar Therapeutics Quarterly Cash Flow Statement
NASDAQ: NKTRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Nektar Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Nektar Therapeutics generated -$75.8 million of operating cash flow and spent $94,000 on capital expenditures. That left free cash flow of -$75.9 million, a free-cash-flow margin of -748.8% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Nektar Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -40.62M | -44.90M | -36.08M | -35.52M | -41.59M | -50.88M | 7.26M | -37.06M | -52.36M | -36.80M | -42.08M | -45.84M |
| Net Income growth (YoY) | — | — | -596.89% | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 156.00K | 151.00K | 190.00K | 196.00K | 214.00K | 426.00K | 332.00K | 993.00K | 1.46M | 1.61M | 1.65M | 1.70M |
| Stock-Based Compensation | 3.37M | 3.35M | 2.19M | 3.07M | 3.49M | 3.90M | 4.80M | 5.39M | 5.42M | 6.00M | 7.25M | 8.15M |
| Change in Working Capital | -25.78M | 15.00K | -14.65M | 664.00K | -2.54M | 452.00K | 366.00K | -2.06M | 3.15M | -5.52M | 7.65M | -1.28M |
| Operating Cash Flow | -75.77M | -44.30M | -64.96M | -48.76M | -45.74M | -49.05M | -46.19M | -43.93M | -37.70M | -47.89M | -47.05M | -42.12M |
| Capital Expenditures | -94.00K | -18.00K | -18.00K | -114.00K | -37.00K | -2.00K | -459.00K | -666.00K | -186.00K | -157.00K | -237.00K | -33.00K |
| Investing Cash Flow | -399.11M | -350.79M | 372.00K | -94.87M | 49.62M | 43.69M | 60.21M | 46.12M | 16.98M | 19.26M | 17.38M | 56.41M |
| Share Repurchases | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3.00M | 0 | 0 |
| Financing Cash Flow | 364.57M | 529.55M | 38.67M | 141.68M | 211.00K | 7.00K | 83.00K | 13.00K | 19.00K | 42.00M | 12.00K | 0 |
| Net Change in Cash | -110.31M | 134.46M | -25.92M | -1.96M | 4.09M | -5.36M | 14.14M | 2.17M | -20.70M | 13.37M | -29.64M | 14.19M |
| Free Cash Flow | -75.86M | -44.32M | -64.98M | -48.88M | -45.77M | -49.05M | -46.65M | -44.60M | -37.89M | -48.05M | -47.28M | -42.15M |
This table shows 12 quarterly periods of Nektar Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow NKTR's reporting calendar. What is a cash flow statement?